Search

Search Constraints

You searched for: Author/Creator Rossini, Daniele

Search Results

1. A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. (9th March 2018)

3. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. (February 2015)

4. Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. Issue 2 (8th March 2019)

5. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. (February 2022)

6. Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. Issue 2 (9th May 2019)

7. EGFR Amplification in Metastatic Colorectal Cancer. (7th April 2021)

8. Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC. Issue 1 (29th March 2017)

9. FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies. (May 2022)

10. FOLFOXIRI‐Bevacizumab or FOLFOX‐Panitumumab in Patients with Left‐Sided RAS/BRAF Wild‐Type Metastatic Colorectal Cancer: A Propensity Score‐Based Analysis. (2nd January 2021)